SAG
CRVS icon

SageView Advisory Group’s Corvus Pharmaceuticals CRVS Stock Holding History

SageView Advisory Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$231 Buy
+30
New +$237 ﹤0.01% 2506

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SageView Advisory Group's CRVS Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Corvus Pharmaceuticals (CRVS) in Q4 2025: 30 shares worth $231. The stake represents ﹤0.01% of the portfolio and ranks #2506 among its holdings.

124 funds tracked by Wall St. Rank hold CRVS as of Q4 2025.

  • SageView Advisory Group held 30 shares of Corvus Pharmaceuticals worth $231 as of Q4 2025.
  • Corvus Pharmaceuticals was a new SageView Advisory Group position in Q4 2025.
  • Corvus Pharmaceuticals made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2506 holding.
  • 124 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.